KYNB
Kyntra BioANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-23
Current thesis
The positive case rests on two dated clinical milestones: a Q4 2026 FG-3246 interim analysis and expected second-half 2026 roxadustat Phase 3 initiation. The reported cash runway into 2028 provides time to reach those milestones.
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
FG-3246 Phase 2 interim results could disappoint or be delayed, creating substantial downside risk.
Momentum
95
Value
61
Sentiment
52
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $7.30 · Bull $11.00 · Bear $4.50
Data freshness
Prices
As of 2026-07-23
Fundamentals
As of 2026-07-23 • Vendor: Data Vendor v1
Scores
As of 2026-07-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-07-22 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-23
Investment thesis
As of 2026-07-23
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $36.00
Why
Momentum95 · Δ7d -
Value61 · Δ7d +0.1
Sentiment52 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
95
26% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
61
39% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
-0.2
Sentiment
52
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade A. Momentum 94.6 / Value 61.2 / Sentiment 51.8
Fundamentals (TTM)As of 2026-07-23
Fundamentals (TTM)
As of 2026-07-23
Market Cap
$28.62M
Beta
0.84
Shares Out
4.05M
P/E (TTM)
0.2
P/S (TTM)
4.35
P/FCF (TTM) · Derived
-1.34
Rev YoY
+36.5%
EPS YoY
-426.9%
Gross Margin
+35.0%
Op Margin
-1574.1%
Net Debt
-$69.42M
Current Ratio
3.61
As of 2026-07-23 • Updated nightlySource: Internal modelMethodology